[The osteoporosis patient with renal insufficiency: what has to be taken into account in the selection and administration of antiosteoporosis medication?].
The incidence of osteoporosis and renal insufficiency increases with age, the use of antiosteoporotic drugs approved for long-term administration in patients with inadequate renal function is therefore a cause for concern. In the dose approved for the treatment of osteoporosis oral bisphosphonates and i.v. ibandronate (3 mg every 12 weeks) have a secure antifracture efficacy, and their use is considered safe in patients with glomerular filtration rate (GFR) > 30 mI/min. Treatment with strontium ranelate and the osteoanabolic substance teriparatide is not altered by impaired renal function until GFR falls below 30 ml/min. Efficiancy of the selective estrogen receptor modulator (SERM) raloxifene is not altered by renal function.
Lehmann
G
G
Funktionsbereich Rheumatologie/Osteologie, Klinik Innere Medizin III der Friedrich Schiller Universität, Jena. Gabriele.Lehmann@med.uni-jena.de
Hein
G
G
Wolf
G
G
D000284:Administration, Oral; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005598:Fractures, Spontaneous / Q000097:blood / Q000517:prevention & control; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications; D008657:Metabolic Clearance Rate / Q000187:drug effects; D010024:Osteoporosis / Q000097:blood / Q000150:complications / Q000188:drug therapy*
D050071:Bone Density Conservation Agents